- Home
- MRSN vs CUE Comparison
MRSN vs CUE Comparison
Compare MRSN & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- CUE
- Stock Information
- Founded
- MRSN 2001
- CUE 2014
- Country
- MRSN United States
- CUE United States
- Employees
- MRSN N/A
- CUE N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- MRSN Health Care
- CUE Health Care
- Exchange
- MRSN Nasdaq
- CUE Nasdaq
- Market Cap
- MRSN 40.7M
- CUE 48.0M
- IPO Year
- MRSN 2017
- CUE 2018
- Fundamental
- Price
- MRSN $0.29
- CUE $0.68
- Analyst Decision
- MRSN Strong Buy
- CUE Strong Buy
- Analyst Count
- MRSN 5
- CUE 3
- Target Price
- MRSN $5.75
- CUE $3.00
- AVG Volume (30 Days)
- MRSN 2.8M
- CUE 313.6K
- Earning Date
- MRSN 08-12-2025
- CUE 08-13-2025
- Dividend Yield
- MRSN N/A
- CUE N/A
- EPS Growth
- MRSN N/A
- CUE N/A
- EPS
- MRSN N/A
- CUE N/A
- Revenue
- MRSN $34,006,000.00
- CUE $7,991,000.00
- Revenue This Year
- MRSN N/A
- CUE N/A
- Revenue Next Year
- MRSN $1.30
- CUE $23.84
- P/E Ratio
- MRSN N/A
- CUE N/A
- Revenue Growth
- MRSN N/A
- CUE 13.83
- 52 Week Low
- MRSN $0.26
- CUE $0.45
- 52 Week High
- MRSN $2.83
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- MRSN 38.23
- CUE 47.91
- Support Level
- MRSN $0.27
- CUE $0.65
- Resistance Level
- MRSN $0.36
- CUE $0.71
- Average True Range (ATR)
- MRSN 0.03
- CUE 0.08
- MACD
- MRSN -0.01
- CUE 0.00
- Stochastic Oscillator
- MRSN 16.81
- CUE 38.62
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.